论文部分内容阅读
目的 对131I-CL3治疗的中晚期食管癌、结直肠癌患者联合应用IL - 2 ,探讨提高中晚期食管癌、结直肠癌放射免疫治疗效果的方法 .方法 中晚期食管癌、结直肠癌患者 2 8例 ,分为131I-CL3治疗组 13例 ,131I-CL3+IL - 2治疗组 15例 .131I-CL3治疗组瘤内注射131I -CL3 1110～ 1480MBq/3～ 4mg/次 ;131I-CL3 +IL - 2治疗组除行相同于131I-CL3治疗组治疗外 ,在瘤内注射131I-CL3前 2周及后 4周加肌注IL - 2 ,每天 2次 ,每次 10万单位 ,全程 6周 ,注射IL - 2总量为 840万单位 .结果 :131I -CL3治疗组有效率 46 .2 % ;1年和 2年生存率分别为15 .4%和 0 % ;T细胞亚群治疗前后变化无差异 (p>0 .0 5 ) .131I-CL3+IL - 2治疗组有效率 6 0 % ;1年和 2年生存率分别为 40 %和 13 .3 % ,明显高于131I-CL3治疗组 (p <0 .0 5 ) ;治疗后CD3+细胞、CD4 +细胞和CD4 +/CD8+较治疗前明显升高 (p <0 .0 5 ) .结论 联合应用IL - 2的131I -CL3放射免疫治疗 ,对延长患者生存时间 ,促进机体免疫应答 ,提高中晚期食管癌、结直肠癌放射免疫治疗疗效十分有益
Objective To investigate the effect of radioimmunotherapy on advanced esophageal cancer and colorectal cancer in patients with advanced esophageal cancer and colorectal cancer treated with 131I-CL3.Methods The patients with advanced esophageal cancer and colorectal cancer 2 8 cases were divided into 13 cases of 131I-CL3 treatment group and 15 cases of 131I-CL3 + IL-2 treatment group.The 131I-CL3 treatment group was injected with 131I-CL3 1110-1480MBq / 3-4mg / IL - 2 treatment group except for the same line 131I-CL3 treatment group, intratumoral injection of 131I-CL3 two weeks before and after 4 weeks plus intramuscular injection of IL - 2 twice daily, each 100,000 units, the whole 6 Week, the total amount of IL - 2 injected was 8.4 million units.Results: The effective rate of 131I - CL 3 treatment group was 46.2%, and the 1 - and 2 - year survival rates were 15.4% and 0% respectively. Before and after treatment of T cell subsets There was no significant difference (p> 0.05) .131I-CL3 + IL-2 treatment group was 60% effective; 1-year and 2-year survival rates were 40% and 13.3%, significantly higher than 131I-CL3 (P <0.05). After treatment, the levels of CD3 + cells, CD4 + cells and CD4 + / CD8 + were significantly higher than those before treatment (p <0.05) .Conclusion The combined use of IL - 2 and 131I - Immunotherapy, to prolong the suffering Survival, and promote the body’s immune response and improve advanced esophageal cancer, colorectal cancer radioimmunotherapy very beneficial effect